Precision Adjuvant Therapy Based on Detailed Pathological Risk Factors for Resected Oral Cavity Squamous Cell Carcinoma: Long Term Outcome Comparison of CGMH and NCCN Guidelines

The evidence for adjuvant therapy of oral cavity squamous cell carcinoma (OCSCC) in NCCN guidelines derives from head and neck cancer patients. Here, we examined whether adjuvant therapy should be guided by a detailed analysis of pathological risk factors in pure OCSCC patients. We propose new indications for adjuvant therapy in resected OCSCC. Our guidelines for adjuvant therapy performed better than NCCN guidelines, with 28% of NCCN intermediate-risk patients potentially avoiding adjuvant therapy.

Source: International Journal of Radiation Oncology * Biology * Physics - September 5, 2019 Category: Radiology Authors: Chien-Yu Lin, Kang-Hsing Fan, Li-Yu Lee, Chuen Hsueh, Lan Yan Yang, Shu-Hang Ng, Hung-Ming Wang, Chia-Hsun Hsieh, Chih-Hung Lin, Chung-Kan Tsao, Chung-Jan Kang, Tuan-Jen Fang, Li-Ang Lee, Shiang-Fu Huang, Kai-Ping Chang, Tzu-Chen Yen, Ze Yun Tay, Yu-Wen W Source Type: research